Market Research Logo

Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) - Pipeline Review, H2 2016

Introduction
Global Markets Direct Report Coverage
Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) Overview
Therapeutics Development
Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) - Products under Development by Stage of Development
Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) - Products under Development by Therapy Area
Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) - Products under Development by Indication
Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) - Products under Development by Companies
Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) - Products under Development by Universities/Institutes
Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) - Companies Involved in Therapeutics Development
Johnson & Johnson
Zealand Pharma A/S
Zeria Pharmaceutical Co., Ltd.
Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) - Drug Profiles
D-217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-26070109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
netazepide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize CCK-2 Receptor for Ulcer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TR-2A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Z-360 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZP-3022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) - Dormant Projects
Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) - Discontinued Products
Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) - Featured News & Press Releases
Jun 06, 2015: Presentations on ZP3022, novel Zealand preclinical peptide therapeutics as a possible approach for the treatment of Type 2 diabetes and obesity at the American Diabetes Association’s (ADA) 74th Scientific Sessions
Sep 27, 2013: Zealand presents new preclinical data on its GLP-1-gastrin dual agonist, which shows potential as a novel approach for the treatment and/or prevention of type 2 diabetes
Oct 04, 2012: Zealand Pharma Presents New Preclinical Data On ZP3022 At EASD 48th Annual Meeting
Sep 26, 2012: Zealand Pharma To Present Preclinical Data Of ZP3022 At EASD 48th Annual Meeting
Jun 10, 2012: Zealand Pharma Presents Positive Preclinical Results Of ZP3022 At ADA Annual Scientific Sessions
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Johnson & Johnson, H2 2016
Pipeline by Zealand Pharma A/S, H2 2016
Pipeline by Zeria Pharmaceutical Co., Ltd., H2 2016
Dormant Projects, H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) - Pipeline Review, H2 2016’, provides in depth analysis on Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) targeted pipeline therapeutics.

The report provides comprehensive information on the Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR)
  • The report reviews Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gastrin/Cholecystokinin Type B Receptor (Cholecystokinin 2 Receptor or CCKBR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;